Quarterly report pursuant to Section 13 or 15(d)

Reverse Recapitalization (Details)

v3.21.2
Reverse Recapitalization (Details)
3 Months Ended 9 Months Ended
May 24, 2021
$ / shares
shares
May 23, 2021
Sep. 30, 2021
USD ($)
$ / shares
shares
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Sep. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Sep. 30, 2021
USD ($)
$ / shares
shares
Business Acquisition [Line Items]                
Deemed dividend - Earnout Shares | $               $ 253,130,272
Earnout shares for common stockholders               22,209,280
Earnout cash for common stockholders | $               $ 88,837,121
Stock Issued During Period, Shares, New Issues     511,065          
Aggregate purchase price | $     $ 1,134,816 $ 1,562,272 $ 6,927,086 $ 1,412,067 $ 177,025  
Substitute Warrants                
Business Acquisition [Line Items]                
Contingent Consideration (in shares)     1,920,492         1,920,492
Substitute Options                
Business Acquisition [Line Items]                
Contingent Consideration (in shares)     935,608         935,608
Merger agreement                
Business Acquisition [Line Items]                
Contingent Consideration (in shares)     25,000,000         25,000,000
Contingent Consideration | $     $ 100,000,000         $ 100,000,000
Number of business days for issue of Earnout shares               5 days
Stock Issued During Period, Shares, New Issues               3,729,730
Merger agreement | Subscription agreements                
Business Acquisition [Line Items]                
Issue price (in dollars per share) | $ / shares     $ 10.00         $ 10.00
Stock Issued During Period, Shares, New Issues               1,000,000
Aggregate purchase price | $               $ 10,000,000
Merger agreement | Stockholders of NeuroRx                
Business Acquisition [Line Items]                
Consideration (in shares) 50,000,000              
Issue price (in dollars per share) | $ / shares $ 0.001              
Exchange Ratio 3.16 4.96